Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Treatment with Asciminib As a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) - a Chart Review Study in the United States

Ehab L. Atallah, Islam Sadek, David Wei, Dominick Latremouille-Viau, Carmine Rossi, Andrea Damon, Daisy Yang, Remi Bellefleur, Annie Guérin, Kejal Jadhav

Blood (2024) 144 (Supplement 1): 3812.

https://doi.org/10.1182/blood-2024-193201

Published: 2024

Journal Articles

Impact of Adverse Events on Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs) - Early Results of the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study

Kelly Schoenbeck, Joan Clements, Karen Demairo, David Wei, Nisha C Hazra, Cristina Constantinescu, Yan Meng, Dominick Latremouille-Viau, Kejal Jadhav, Courtney McDermott, Daisy Yang, Andrea Damon, Islam Sadek, Annie Guerin, Kathryn E. Flynn

Blood (2024) 144 (Supplement 1): 7913.

https://doi.org/10.1182/blood-2024-207213

Published: 2024

Journal Articles

Intravenous Treatment Workflow for Paroxysmal Nocturnal Hemoglobinuria from the Perspective of Nurses and Pharmacists in US Clinical Practices

Daniel Winokur, Brian Mulherin, Abdulraheem Yacoub, Soyon Lee, Ver Bilano, Glorian Yen, Anumaxine Geevarghese, Jincy Paulose, Annie Guerin, Dominick Latremouille-Viau, Rebecca Bungay, Gayatri Marathe, Anem Waheed

Blood (2024) 144 (Supplement 1): 7553.

https://doi.org/10.1182/blood-2024-199147

Published: 2024

Journal Articles

Treatment Patterns and Modifications of Tyrosine Kinase Inhibitors (TKI) Therapy in Early Lines in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Real-World Analysis from a Large Commercial Claims Database in the United States (US)

Vamsi K. Kota, David Wei, Daisy Yang, Hela Romdhani, Dominick Latremouille-Viau, Annie Guérin, Kejal Jadhav

Blood (2023) 142 (Supplement 1): 5190.

https://doi.org/10.1182/blood-2023-180789

Published: 2023

Journal Articles

Oral Anticoagulant (OAC) Use Among Medicare Patients Newly Diagnosed with Venous Thromboembolism (VTE): Factors Associated with Treatment Status

James C Coons, Aolin Wang, Dominick Latremouille-Viau, Cristina Russ, Dong Cheng, Robert Stellhorn, Feng Dai, David R Steffen, Abigail Zion, Serina Deeba, Dionne M Hines

Blood (2023) 142 (Supplement 1): 2363.

https://doi.org/10.1182/blood-2023-172922

Published: 2023

Journal Articles

Incremental Healthcare Resource Utilization and Costs Associated with Non-Optimal Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKI) in Early Lines of Therapy in the United States (US)

Vamsi K. Kota, David Wei, Daisy Yang, Hela Romdhani, Dominick Latremouille-Viau, Annie Guérin, Kejal Jadhav

Blood (2023) 142 (Supplement 1): 5098.

https://doi.org/10.1182/blood-2023-180772

Published: 2023

Journal Articles

Incremental Burden Associated with Dose Escalation in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Complement Inhibitors

Srinivas K. Tantravahi, Dominick Latremouille-Viau, Raj Desai, Soyon Lee, Jincy Paulose, Lincy Geevarghese, Annie Guérin, Shravanthi Seshasayee, Nadia Tabatabaeepour, Glorian P. Yen

Blood (2023) 142 (Supplement 1): 5119.

https://doi.org/10.1182/blood-2023-180759

Published: 2023

Journal Articles

Real-World Evaluation of Treatment Patterns and Clinical Outcomes Among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Asciminib in US Clinical Practice

Ehab L. Atallah, David Wei, Dominick Latremouille-Viau, Carmine Rossi, Andrea Damon, Germano Ferreira, Annie Guerin, Kejal Jadhav

Blood (2023) 142 (Supplement 1): 1809.

https://doi.org/10.1182/blood-2023-178722

Published: 2023

Journal Articles

Treatment Patterns and Healthcare Resource Utilization in Patients with Multiple Myeloma and Baseline Renal Impairment

Parameswaran Hari, MD MRCP, Lita Araujo, Dominick Latremouille-Viau, MSc, Peggy Lin, PhD, Mikhail Davidson, Annie Guerin, MSc, Medha Sasane

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-134597

Published: 2020

Journal Articles

Real-World Treatment Patterns, Healthcare Resource Utilization and Associated Costs Among Patients with Chronic Myeloid Leukemia in Later Lines of Therapy

Ehab L. Atallah, MD, Rodrigo Maegawa, MD, Dominick Latremouille-Viau, MSc, Carmine Rossi, PhD, Annie Guerin, MSc, Pallavi Patwardhan, PhD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-136074

Published: 2020

Journal Articles

Effectiveness of Second-Line (2L) Tyrosine Kinase Inhibitor (TKI) Therapy after Resistance or Intolerance to a Prior TKI in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP)

Sudipto Mukherjee, MD PhD MPH, Xiting Cao, Islam Sadek, Rodrigo Maegawa, MD, Dominick Latremouille-Viau, MSc, Irina Pivneva, Annie Guérin, B. Douglas Smith, MD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-137079

Published: 2020

Journal Articles

Tyrosine Kinase Inhibitor Therapy Discontinuation in Clinical Practice in Chronic Myeloid Leukemia - a US Physician Survey Conducted after Guideline Updates

Ehab L. Atallah, MD, Islam Sadek, Xiting Cao, Dominick Latremouille-Viau, Irina Pivneva, PhD, Carmine Rossi, Annie Guerin, Vamsi Kota, MBBS

Blood (2019) 134 (Supplement_1): 2208.

https://doi.org/10.1182/blood-2019-125736

Published: 2019

Journal Articles

Vaso-Occlusive Crises and Costs of Sickle Cell Disease from a Commercial Payer's Perspective

George J Joseph, Dominick Latremouille-Viau, Vikash Kumar Sharma, Patrick Gagnon-Sanschagrin, Menaka Bhor, PhD, Ankur Khare, Mukesh Kumar Singh, Elizabeth Serra, Mikhail Davidson, Annie Guerin, Nirmish Shah

Blood (2019) 134 (Supplement_1): 3464.

https://doi.org/10.1182/blood-2019-124920

Published: 2019

Journal Articles

Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis

Eytan M. Stein, MD, Dominick Latremouille-Viau, George J Joseph, Sherry Shi, Annie Guerin, MSc, Eric Q Wu, Gaetano Bonifacio, Xiting Cao

Blood (2019) 134 (Supplement_1): 3495.

https://doi.org/10.1182/blood-2019-124878

Published: 2019

Journal Articles

Comparison of Healthcare Resource Utilization and Costs Related to Infections between Patients Newly Diagnosed with Chronic Myeloid Leukemia Treated with Dasatinib and Nilotinib As First-Line Therapy in the United States

Karen Seiter, MD, Dominick Latremouille-Viau, Annie Guerin, MS, Briana Ndife, MPH, Karen Habucky, PhD, George J Joseph, BPharm, MS, PhD, Irina Pivneva, PhD, Patrick Gagnon-Sanschagrin, MS, Derek H Tang, BSPharm, PhD

Blood (2017) 130 (Supplement 1): 3391.

https://doi.org/10.1182/blood.V130.Suppl_1.3391.3391

Published: 2017

Journal Articles

Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in US Clinical Practice, with a Focus on Tyrosine Kinase Inhibitor Therapy Discontinuation

Ellen K Ritchie, MD, Dominick Latremouille-Viau, Annie Guerin, MS, Irina Pivneva, PhD, Karen Habucky, PhD, Briana Ndife, MPH, George J Joseph, BPharm, MS, PhD, Ehab Atallah, MD

Blood (2017) 130 (Supplement 1): 3396.

https://doi.org/10.1182/blood.V130.Suppl_1.3396.3396

Published: 2017

Journal Articles

Reduction in Healthcare Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia (CML) with Better Adherence to Tyrosine Kinase Inhibitors (TKIs) and Increased Molecular Monitoring Frequency

Dominick Latremouille-Viau, MSc, Annie Guerin, MSc, Patrick Gagnon-Sanschagrin, BSc, Katherine Dea, MSc, Benjamin Cohen, MPH, George J Joseph, BPharm, MS, PhD

Blood (2016) 128 (22): 2398.

https://doi.org/10.1182/blood.V128.22.2398.2398

Published: 2016

Journal Articles

Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Eytan M. Stein, MD, Dominick Latremouille-Viau, MSc, Annie Guerin, MSc, Sherry Shi, MSc, Patrick Gagnon-Sanschagrin, BSc, Gaetano Bonifacio, MD, George J Joseph, BPharm, MS, PhD

Blood (2016) 128 (22): 5929.

https://doi.org/10.1182/blood.V128.22.5929.5929

Published: 2016

Journal Articles

Treatment Patterns and Healthcare Costs in Newly Diagnosed Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As First-Line Therapy in the United States: A Retrospective Claims Database Analysis

Lei Chen, MD PhD, Dominick Latremouille-Viau, MSc, Annie Guerin, MSc, Roy Nitulescu, MSc, Patrick Gagnon-Sanschagrin, BSc

Blood (2015) 126 (23): 1596.

https://doi.org/10.1182/blood.V126.23.1596.1596

Published: 2015

Journal Articles

Comparison of Survival Rates, Healthcare Resource Use and Costs of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As Second-Line Therapy

B. Douglas Smith, MD, Jun Liu, PhD, Dominick Latremouille-Viau, MSc, Zhou Zhou, MSc, Annie Guerin, MSc, Daniel Fernandez, MA, Dingdong Yi, BS, Xufei Wang, MA, Eric Q Wu, PhD, Shivani K Mhatre, MSc, Christopher H Keir, MD, Lei Chen, MD PhD

Blood (2014) 124 (21): 2618.

https://doi.org/10.1182/blood.V124.21.2618.2618

Published: 2014

NARROW

Treatment with Asciminib As a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) - a Chart Review Study in the United States

Impact of Adverse Events on Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs) - Early Results of the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study

Intravenous Treatment Workflow for Paroxysmal Nocturnal Hemoglobinuria from the Perspective of Nurses and Pharmacists in US Clinical Practices

Treatment Patterns and Modifications of Tyrosine Kinase Inhibitors (TKI) Therapy in Early Lines in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Real-World Analysis from a Large Commercial Claims Database in the United States (US)

Oral Anticoagulant (OAC) Use Among Medicare Patients Newly Diagnosed with Venous Thromboembolism (VTE): Factors Associated with Treatment Status

Incremental Healthcare Resource Utilization and Costs Associated with Non-Optimal Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKI) in Early Lines of Therapy in the United States (US)

Incremental Burden Associated with Dose Escalation in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Complement Inhibitors

Real-World Evaluation of Treatment Patterns and Clinical Outcomes Among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Asciminib in US Clinical Practice

Treatment Patterns and Healthcare Resource Utilization in Patients with Multiple Myeloma and Baseline Renal Impairment

Real-World Treatment Patterns, Healthcare Resource Utilization and Associated Costs Among Patients with Chronic Myeloid Leukemia in Later Lines of Therapy

Effectiveness of Second-Line (2L) Tyrosine Kinase Inhibitor (TKI) Therapy after Resistance or Intolerance to a Prior TKI in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP)

Tyrosine Kinase Inhibitor Therapy Discontinuation in Clinical Practice in Chronic Myeloid Leukemia - a US Physician Survey Conducted after Guideline Updates

Vaso-Occlusive Crises and Costs of Sickle Cell Disease from a Commercial Payer's Perspective

Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis

Comparison of Healthcare Resource Utilization and Costs Related to Infections between Patients Newly Diagnosed with Chronic Myeloid Leukemia Treated with Dasatinib and Nilotinib As First-Line Therapy in the United States

Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in US Clinical Practice, with a Focus on Tyrosine Kinase Inhibitor Therapy Discontinuation

Reduction in Healthcare Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia (CML) with Better Adherence to Tyrosine Kinase Inhibitors (TKIs) and Increased Molecular Monitoring Frequency

Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Treatment Patterns and Healthcare Costs in Newly Diagnosed Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As First-Line Therapy in the United States: A Retrospective Claims Database Analysis

Comparison of Survival Rates, Healthcare Resource Use and Costs of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As Second-Line Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only